For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

“...we have a 100% success rate to date in the patients that have been treated long enough to evaluate for benefit.”

Roisin McGuigan, Commissioning Editor, Nucleic Acid Insights, speaks to Stanley Crooke, Chairman, Founder and CEO, n-Lorem, about his long career and pioneering role in the antisense oligonucleotide (ASO) space, how RNA-targeting therapies are set to enter the mainstream, and his latest focus: making personalized, free-for-life ASO therapies available to nano-rare patient populations.

Please enter your email to access content Read now